American Society of Hematology

SHERPA: Blue

People

  1. Abdel-Wahab
    Abdel-Wahab
  2. Levine
    Levine
  3. Rampal
    Rampal
  4. Park
    Park
  5. Durham
    Durham
  6. Stein
    Stein
  7. Diamond
    Diamond
  8. Dogan
    Dogan
  9. Derkach
    Derkach
  10. Gonen
    Gonen

Groups

  1. Adult Leukemia (82)
  2. Center for Hematologic Malignancies (82)
  3. Department of Medicine (82)
  4. Executive Committee, Center for Hematologic Malignancies (82)
  5. GSK Faculty (82)
  6. Hematologic Malignancies, Division of (82)
  7. Human Oncology and Pathogenesis Program (82)
  8. Tow Center for Developmental Oncology (TCDO) (82)
  9. Sloan Kettering Institute Postdocs (31)
  10. Sloan Kettering Institute Faculty (16)
Search Within
  1. "Meeting abstract"
  2. "Human Oncology and Pathogenesis Program"
  3. "Omar Abdel-Wahab"
  4. "Blood"
  5. "Adult Leukemia"
Formats
  1. Meeting Abstract (82)
Groups
  1. Adult Leukemia (82)
  2. Center for Hematologic Malignancies (82)
  3. Department of Medicine (82)
  4. Executive Committee, Center for Hematologic Malignancies (82)
  5. GSK Faculty (82)
  6. Hematologic Malignancies, Division of (82)

More Groups

People
  1. Omar Abdel-Wahab (82)
  2. Ross Levine (47)
  3. Martin Tallman (29)
  4. Jae Park (15)
  5. Raajit Rampal (15)
  6. Young Rock Chung (14)

More People

Years
  1. 2023 (3)
  2. 2022 (5)
  3. 2021 (3)
  4. 2020 (6)
  5. 2019 (3)
  6. 2018 (5)

More Years

Publications
  1. Blood (82)

Results (82)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • E7820, an anti-cancer sulfonamide, in combination with venetoclax in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial
    Meeting Abstract

    Bewersdorf, J. P.; Chandhok, N. S.; Watts, J. M.; Derkach, A.; Abdel-Wahab, O.; Stein, E. M.; Taylor, J.
    Blood (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of single-agent cobimetinib for adults with histiocytic neoplasms
    Meeting Abstract

    Diamond, E. L.; Durham, B.; Dogan, A.; Yabe, M.; Petrova-Drus, K.; Rampal, R. K.; Ulaner, G.; Lacouture, M.; Rotemberg, V.; Covey, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes
    Meeting Abstract

    Bewersdorf, J. P.; Stahl, M. F.; Taylor, J.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Kostantakis, V.; Lu, S. X.; Bourcier, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • NX-2127-001, first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies
    Meeting Abstract

    Mato, A. R.; Wierda, W. G.; Ai, W. Z.; Flinn, I. W.; Tees, M.; Patel, M. R.; Patel, K.; O'Brien, S.; Bond, D. A.; Roeker, L. E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Characteristics and prognostic effects of DNMT3A co-mutations
    Meeting Abstract

    Torabi, A.; Alonzo, T. A.; Othus, M.; Gerbing, R. B.; Wang, Y. C.; Ries, R. E.; Radich, J. P.; Appelbaum, F. R.; O'Dwyer, K.; Erba, H. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save